HKG:6990

5 stories mentioning HKG:6990Updated 12d ago

Every FINWIRES story that references HKG:6990, newest first.

Sichuan Kelun-Biotech Receives Nearly 603 Million Yuan From MediLink

Sichuan Kelun-Biotech Biopharmaceutical (HKG:6990) said it received a further 602.5 million yuan from MediLink Therapeutics as part of a licensing settlement involving YL201, according to a Friday filing with the Hong Kong bourse.The firm said it had so far received 702.7 million yuan from MediLink Therapeutics.Sichuan Kelun-Biotech previously pursued criminal proceedings against MediLink Therapeutics over allegations the firm misappropriated its trade secrets.Both sides then reached a settlement under an out-licensing deal covering several drugs, including YL201.

HKG:6990

Asia30d ago

Nomura Adjusts Sichuan Kelun-Biotech Biopharmaceutical's Price Target to HK$544.42 From HK$438.30, Keeps at Buy

Sichuan Kelun-Biotech Biopharmaceutical Co (HKG:6990) has an average rating of buy and mean price target of HK$550.70, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

HKG:6990

Asia33d ago

Kelun Biotech to Present Study Results of Cancer Drugs at American Oncology Meeting

Sichuan Kelun-Biotech Biopharmaceutical (HKG:6990) will present the results of its registrational studies on sacituzumab tirumotecan (sac-TMT) and lunbotinib fumarate at the 2026 American Society of Clinical Oncology annual meeting, according to a filing by parent Sichuan Kelun Pharmaceutical (SHE:002422) with the Shenzhen bourse.Its study on its sacituzumab tirumotecan drug versus pembrolizumab for advanced non-small cell lung cancer treatment showed a higher response rate for its sac-TMT against pembrolizumab, the filing said.The company will also present results from its study on lunbotinib, which showed an objective response rate of 87.1% on patients with RET-fusion positive non-small cell lung cancer in patients with prior chemotherapy.

HKG:6990SHE:002422

Asia43d ago

Sichuan Kelun-Biotech Wins China IND Nod for Cancer Therapy

Sichuan Kelun-Biotech Biopharmaceutical (HKG:6990) received approval from China's National Medical Products Administration for the investigational new drug application of SKB118, according to a Wednesday Hong Kong bourse filing.The company said the PD-1/VEGF bispecific antibody is intended for the treatment of advanced solid tumors.The approval clears the company to begin clinical trials for the drug candidate in China, the filing said.

HKG:6990

Asia47d ago

SKB Biopharma's Application for New Indication of Tumor Drug Accepted in China

Sichuan Kelun-Biotech Biopharmaceutical's (HKG:6990) new indication application for sacituzumab tirumotecan was accepted for review by China's National Medical Products Administration, according to a Friday Hong Kong bourse filing.The application is for the drug in combination with pembrolizumab as first-line treatment for adult patients with locally advanced or metastatic non-small cell lung cancer.

HKG:6990

Track with the FINWIRES app suite

FolioX

Track HKG:6990 in your portfolio

WheelAI

Analyze HKG:6990 options with the wheel strategy

StockInsider

See market sentiment on HKG:6990